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Abstract
Background: International thyroid nodule and cancer management guide-
lines generally fail to take into account potential limitations in diagnostic and
treatment resources.
Methods: Thyroid cancer specialists from the African Head and Neck Society
and American Head & Neck Society Endocrine Section developed guidelines
for diagnosis and management of thyroid nodules and cancer in low resource
settings. Recommendations were based on literature review and expert opin-
ion, with level of evidence defined.
Results: Using the ADAPTE process, diagnostic and treatment algorithms
were adapted from the National Comprehensive Cancer Network (NCCN).
Low resource settings were simulated by systematically removing elements
such as availability of laboratory testing, hormone replacement, imaging, and
cytopathology from NCCN guidelines.
Conclusions: Successful management of thyroid nodules and cancer in low
resource settings requires adaptation of treatment methodologies. These guide-
lines define specific scenarios where either more or less aggressive intervention
for thyroid pathology may be advisable based on limited available resources.
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1 | INTRODUCTION
Thyroid nodules are common and are estimated to occur
in at least 33% of the population.1 Studies suggest that
approximately 95% of thyroid nodules are benign and will
not progress to malignant disease.2,3 However, the rate of
malignancy within thyroid nodules may be higher in low
resource settings,4 specifically since nodules are more fre-
quently detected when clinically apparent rather than
incidentally. Moreover, approximately 90% of malignant
thyroid cancers are well-differentiated histological
variants,5 with the majority diagnosed as papillary (PTC),
follicular (FTC), or Hürthle cell thyroid cancers (HTC).
In iodine sufficient regions, PTCs are by far the most
common subtype, while follicular cancers have been
reported as relatively more common in iodine deficient
regions.6,7 Because differentiated cancers are generally
slow-growing and have a good prognosis,8,9 treatment of
differentiated thyroid cancer has become more conserva-
tive with observation being a reasonable option for small
(<1 cm) low-risk PTCs in patients with reliable follow-
up,10 and less extensive surgery and less frequent use of
radioactive iodine employed for low risk differentiated
cancers.11,12
Many thyroid nodules and cancers are diagnosed inci-
dentally by ultrasound (U/S) and other imaging modali-
ties. However, radiological screening for thyroid nodules
and cancers is not recommended.13 Because the majority
of thyroid nodules are not life threatening and hence do
not require surgery, investigation of a thyroid nodule is
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directed at identifying the minority of cases that require
thyroid surgery, as opposed to observation or simple reas-
surance. The principal diagnostic tools used for thyroid
nodules and cancers and to avoid unnecessary surgery
are thyroid U/S and fine needle aspiration cytology
(FNAC).14
International guidelines for management of thyroid
nodules and cancers such as those of the American Thy-
roid Association (ATA) and National Comprehensive
Cancer Network (NCCN) assume the availability of thy-
roid stimulating hormone (TSH) assays, U/S, FNAC, thy-
roid scans, radioactive iodine (RAI), thyroid and calcium
monitoring and replacement, and reliable follow-up.15,16
However, in low resource settings, such as those found in
developing countries, these studies and interventions fre-
quently are not available or are unaffordable.7,17 Compli-
ance and/or scheduling of follow-up examinations may
also be unreliable. Hence, international guidelines for
management of thyroid nodules and cancers often cannot
be applied to low resource settings.
Without resource-appropriate guidelines for thyroid
nodules and cancers, domestic surgeons (and even volun-
teer surgeons visiting from higher-resource settings) have
little guidance with regard to best practice when working
in limited-resource settings. Failure to take resource limi-
tations into account may lead to inappropriate surgery,
over-investigation or, in the worst-case scenario, even
have life-altering or fatal consequences associated with
unforeseen perioperative complications or postoperative
sequelae. Herein are presented diagnostic and treatment
guidelines for management of thyroid nodules and thy-
roid cancer in low resource settings.
2 | METHODS
The African Head and Neck Society (AfHNS) convened a
task force of thyroid specialists to review thyroid nodule
and thyroid cancer management guidelines for low
resource settings, with a particular focus on preoperative,
perioperative, and postoperative decision making. This
international collaboration included otolaryngologists
and general surgeons with expertise in head and neck
endocrine surgery from across the globe, including mem-
bers of the AfHNS and American Head & Neck Society
(AHNS) Endocrine Section. The task force met in Cape
Town in December 2018.
A comprehensive literature review using the PubMed
and Cochrane libraries was performed. The search strat-
egy used the following algorithm: (“thyroid cancer” or
“thyroid neoplasm” or “thyroid nodule” or “thyroid carci-
noma”) and (“evaluation” OR “diagnosis” or “imaging”
or “management” or “treatment” or “neck dissection” or
“surgery”) and (“developing” or “resource poor” or “low
resource” or “underdeveloped” or “less developed” or
“emerging” or “third world”) and (“Countries” or
“Nations” or “Area” or “Region”).
The information gathered in this literature review
guided the development of task force recommendations—
with supplementation by expert opinion and society guide-
lines when information regarding a particular subject was
lacking. In particular, the 2018 NCCN Clinical Practice
Guidelines for thyroid carcinoma were used as a frame-
work and adapted for limited resource settings. Low
resource scenarios were created by systematically remov-
ing elements, such as availability of TSH, U/S, RAI, and so
on, from the NCCN diagnostic and management criteria.
The task team used the ADAPTE process, a validated sys-
tematic approach to amending evidence-based clinical
practice guidelines (Figure 1), to modify diagnostic and
treatment protocols developed for resource-rich environ-
ments to account for the constraints of low resource set-
tings.18 Each recommendation that was developed was
categorized based on the level of evidence and consensus,
similar to system utilized by the NCCN16:
Category 1: high level evidence and uniform consen-
sus of the authors.
FIGURE 1 Summary of the ADAPTE process used to create
low resource guidelines for thyroid nodule and cancer management
[Color figure can be viewed at wileyonlinelibrary.com]
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Category 2A: lower-level evidence with uniform con-
sensus of the authors.
Category 2B: lower-level evidence with consensus
(not uniform) of the authors.
Category 3: any level of evidence where there is sig-
nificant disagreement between the authors.
It should be noted that there are many reasons why a
particular resource could be considered “unavailable,”
including a lack of technology or equipment, delays in
availability of resources, and/or poor quality of available
resources. In this study, we consider low-resource envi-
ronments as any setting where particular resources are
either physically unavailable, financially unavailable, or
practically unavailable if the quality of the test is poor on
account of inadequate equipment (eg, ultrasound or FNA
equipment) or expertise (eg, radiologist/surgeon experi-
enced with thyroid ultrasound or pathologist capable of
interpreting thyroid cytopathology). Therefore, a low
resource setting can refer to a rural or less developed
region within a more developed country, or to a particu-
lar patient for whom resources are inaccessible even
within an otherwise resource-rich region.
3 | RECOMMENDATIONS
3.1 | Evaluation of thyroid nodule or
mass in low resource settings
Nodularity of the thyroid gland is common in the general
population, and the majority of thyroid nodules are
benign and do not require surgical excision.3,19 Nodules
may be detected on incidental neck palpation or by U/S
imaging, with the important caveat that standardized
screening for healthy adults is not recommended by the
U.S. Preventative Services Task Force.13 Thyroid cancer
is estimated to be present in approximately 5% of thyroid
nodules,3,20 although this rate may be higher in low
resource settings.4
To rule out thyroid cancer, the standard diagnostic
workup consists of a thyroid U/S with FNAC.15,16 Ultra-
sound is universally agreed to be the most sensitive and
specific initial imaging modality for thyroid nodules, and
while U/S is generally available in most settings, the
quality of the U/S varies substantially with the experience
of the ultrasonographer. Additionally, in high-resource
settings, indeterminate thyroid nodules can be evaluated
with molecular genetics to aid in risk stratification,15 but
this resource-intense and expensive technology is almost
never available in low resource settings.
Serum TSH is standardly checked to evaluate thyroid
function at the time of thyroid nodule evaluation. When
TSH is not available, clinical signs and symptoms may
be used to determine the probability of a hyperthyroid
or euthyroid/hypothyroid state. A clinically validated
method is Wayne's Index, with reported positive predic-
tive value of 95% and negative predictive value of 90%21,22
(Table 1). In situations of hyperthyroidism, a radioactive
iodine uptake test may be employed to evaluate the func-
tionality of a thyroid nodule.23 As any combination of
these studies may not be available in low resource set-
tings (Figure 2), clinicians must often rely on alternative
clinical evaluation and diagnostic criteria.
Recommendation 1: When U/S is unavailable, the
history and physical examination of the thyroid and
neck may yield features suggestive of higher risk of
malignancy, such as rapid growth, firm mass, thyroid
asymmetry, cervical lymphadenopathy, recent onset of
hoarseness, and vocal cord paralysis. When U/S is
unavailable, these high-risk clinical features are indica-
tions for FNAC.
Level of evidence: 2A.
Recommendation 2: CT or MRI should be consid-
ered to assess a thyroid nodule only when U/S is not
available. These imaging modalities have poorer sensitiv-
ity and specificity and are more expensive than U/S.
Level of evidence: 1.
Recommendation 3: Clinical signs and symptoms
may be used to determine the probability of a hyperthy-
roid or euthyroid/hypothyroid state when TSH testing is
not available. Wayne's Index can be used as a clinically
validated assessment score.
Level of evidence: 2A.
Recommendation 4: Other than a rapidly growing
thyroid mass, biopsy of a thyroid nodule is typically not
urgent, and referral to a better-resourced center for
FNAC is recommended if possible.
Level of evidence: 1.
Recommendation 5: If referral for FNAC is not pos-
sible, clinical and U/S findings may be employed to risk-
stratify thyroid nodules using the Thyroid Imaging
Reporting and Data System (TI-RADS) (http://
tiradscalculator.com/). Patients with high-risk clinical
and sonographic features are advised to have surgery
with histopathologic review of the thyroid specimen.
Level of evidence: 1.
3.2 | Surgical options for thyroid tumors
in low-resource settings
Surgical intervention may be indicated for thyroid nod-
ules or cancer in low resource settings for either diagnos-
tic evaluation or definitive management. While FNAC is
the preferred diagnostic methodology, a diagnostic lobec-
tomy (or nodulectomy in select cases) may be performed
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to determine tumor histopathology when FNAC is
unavailable. Complete thyroid lobectomy is preferred
over thyroid nodulectomy in cases where adequate thy-
roid hormone is available, unless the nodule is located in
the isthmus, wherein a thyroid isthmusectomy may be
performed.
However, situations in which patients do not have
access to thyroid hormone monitoring and replacement
require careful consideration. On the one hand, approxi-
mately 25% of thyroid lobectomy patients ultimately
develop hypothyroidism,24,25 with resultant quality of life
implications in patients who are not adequately sup-
plemented with thyroid hormone. On the other hand, all
other things considered, it is generally safest to perform a
complete thyroid lobectomy with identification of the
recurrent laryngeal nerve (RLN), rather than a thyroid
nodulectomy, where the RLN may not be identified and
therefore could be at increased risk for injury. Addition-
ally, when considering a thyroid nodulectomy, the loca-
tion of the nodule within the thyroid gland is an
important factor, with superficially located anterior,
superior, and inferior thyroid nodules posing much less
risk of nerve injury with excision than posterior nodules.
In a low-resource setting without access to thyroid hor-
mone, a surgeon must carefully weigh the risk of lifelong
hypothyroidism with the risk of RLN injury, considering
the size and location of the thyroid nodule.
For diagnosed thyroid carcinoma, surgical resection is
generally recommended as a primary form of treatment
in the vast majority of cases.16 However, in a low-
TABLE 1 Clinical assessment
scores for Wayne's Index
Symptoms Score Signs Present Absent
Preference for cold 5 Hyperkinesia 4 −2
Excessive sweating 3 Atrial fibrillation 4 0
Appetite increased 3 Palpable thyroid 3 −3
Weight decreased 3 Pulse >90 beats/min 3 0
Palpitations 2 Bruit over thyroid 2 -2
Tiredness 2 Exophthalmos 2 0
Nervousness 2 Lid retraction 2 0
Dyspnea on effort 1 Hands hot 2 -2
Appetite decreased −3 Lid lag 1 0
Weight increased −3 Hands moist 1 −1
Preference for heat −5 Pulse >80 beats/min 0 −3
Note: Score of >19 indicates hyperthyroidism; score of <11 indicates euthyroid state.
FIGURE 2 Guidelines for evaluation of a thyroid mass without U/S, TSH, thyroid scan, and FNAC [Color figure can be viewed at
wileyonlinelibrary.com]
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resource setting, the degree of thyroid resection should
be carefully considered in light of how the extent of thy-
roid surgery may influence perioperative complications
and long-term quality of life. Total thyroidectomy is not
recommended in settings without adequate thyroid hor-
mone and/or calcium monitoring and replacement. As
approximately 25% of thyroid lobectomies patients have
been found to develop hypothyroidism,24,25 even thyroid
lobectomies must be carefully evaluated in low resource
settings. Similarly, hypoparathyroidism can be a fatal
perioperative complication and remains a possible con-
traindication to total thyroidectomies when adequate
supplementation is unavailable.
In environments where total thyroidectomy cannot
be safely performed due to aforementioned resource con-
straints, a thyroid lobectomy or subtotal thyroidectomy
may be considered. The Dunhill procedure is a type of
subtotal thyroidectomy procedure that involves complete
removal of one thyroid lobe with preservation of the
superior and posterior thyroid on the contralateral side.
With this procedure, the posterior thyroid tissue near the
cricothyroid joint is preserved, with the intent of not dis-
turbing the RLN, although failure to identify the nerve
does potentially pose increased risk of injury. Similarly,
the intent of preservation of the superior and posterior
thyroid tissue is to increase the likelihood of preservation
of the superior parathyroid glands, which are generally
located along the posterosuperior aspect of the gland.
Risks of subtotal thyroidectomy include hemorrhage,
RLN injury, tumor recurrence, and the understanding
that any future revision surgery will be more challenging
in a setting of incomplete thyroid removal.26
Recommendation 6: Surgeries less than total thy-
roidectomy should be performed when a patient does not
have reliable access to postoperative thyroid or calcium
monitoring and replacement.
Level of evidence: 2A
Recommendation 7: If FNAC is not available, an
open surgical excisional biopsy may be performed in
patients with high-risk clinical and sonographic features.
For patients with access to thyroid hormone monitoring
and replacement, diagnostic complete thyroid lobectomy
should be performed rather than nodulectomy.
Level of evidence: 2A.
Recommendation 8: For patients without access to
thyroid hormone monitoring and replacement, a thyroid
nodulectomy may be considered in the diagnostic evalua-
tion and management of thyroid nodules. Nodules in the
thyroid isthmus or positioned anteriorly within the thy-
roid are most favorable for diagnostic nodulectomy, as
risk to the RLN and parathyroid glands are lower for
nodules in these locations. It must be recognized that
while nodulectomy may decrease incidence of
postoperative hypothyroidism as compared to thyroid
lobectomy, risk of injury to the RLN may be increased
depending on the location of the nodule within the thy-
roid, the trajectory of the RLN, and the experience of the
surgeon. Nodulectomy for posteriorly located thyroid
nodules should be avoided due to higher risk of RLN
injury.
Level of evidence: 2B.
Recommendation 9: Subtotal thyroidectomy (eg,
Dunhill procedure) is a surgical option for patients with
benign thyroid goiters and thyroid cancers who require
bilateral thyroid surgery but who cannot undergo total
thyroidectomy due to lack of access to thyroid or calcium
monitoring and replacement.
Level of evidence: 2A.
3.3 | Management of papillary thyroid
cancer in low-resource settings
PTC accounts for approximately 85% of all thyroid carci-
nomas, although this rate is lower in iodine deficient
regions due to a higher incidence of FTC.6,7 PTC is a
well-differentiated thyroid cancer that is generally associ-
ated with slow tumor growth and good prognosis and
outcomes.27 Most cases of PTC occur sporadically, but
some known risk factors include radiation exposure to
the neck and genetic syndromes including familial ade-
nomatous polyposis and Cowden syndrome.28,29
Initial management of PTC is often stratified based
on tumor size. Large tumors (>4 cm) generally are rec-
ommended for total thyroidectomy with possible central
neck dissection, whereas small tumors (<4 cm) may be
treated by either a lobectomy or total thyroidectomy.16
High-risk tumor features include large tumor size
(>4 cm), significant gross extrathyroidal or extranodal
extension, bulky cervical lymph node metastases, and
distant metastases. Postoperative RAI presupposes that
the thyroid gland has been removed, and therefore these
high-risk features often become indications for upfront
total thyroidectomy.15 However, in low resource settings
wherein RAI is not available, the decision for total thy-
roidectomy should not be based upon indications for
postoperative RAI.
In appropriately resourced settings, elective central
neck dissection is generally only recommended for larger
(> 4 cm) papillary thyroid cancers, and often it is not
recommended electively in any circumstance.30 In low-
resource settings, especially in environments where cal-
cium monitoring and replacement are not readily avail-
able, all four parathyroid glands cannot be put at risk, as
the risk of harm from life-threatening hypoparathyroid-
ism and hypocalcemia outweigh any potential benefit.
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Therefore, when calcium monitoring and replacement
are not available, unilateral papillary thyroid cancer can
safely be treated with unilateral surgery (thyroid ± cen-
tral lymph node dissection in appropriate cases), whereas
modifications to the surgical plan must be made for cases
with bilateral disease such that all four parathyroid
glands are not put at significant risk (typically precluding
total thyroidectomy and/or bilateral central compartment
dissection). Additionally, since gross intraoperative
assessment of lymph nodes generally has poor correlation
with final pathology, surgeons in low resource environ-
ments should especially exercise caution in putting all
four parathyroid glands at risk in any situation based on
presence of intraoperatively identified lymph nodes.
Recommendation 10: In situations when thyroid
and calcium replacement are unavailable, management
of PTC may be stratified based on the extent of disease.
For a tumor less than 2 cm in size with no gross
extrathyroidal extension in a patient less than 55 years
old, observation with follow-up U/S may be most appro-
priate. For thyroid cancers larger than 2 cm that do not
extend to the contralateral lobe, the recommended sur-
gery is either a lobectomy or nodulectomy. In cases
where more extensive disease is present bilaterally, a sub-
total thyroidectomy may be performed if the disease can
be completely excised while still preserving sufficient thy-
roid remnant and avoiding putting all four parathyroid
glands at risk. A unilateral central neck dissection may
be performed in patients with clinically apparent or FNA
proven lymph node metastases (Figure 3).
Level of evidence: 2A.
Recommendation 11: In an environment wherein
RAI is unavailable, a thyroid lobectomy is recommended
for unilateral PTC, regardless of tumor size, extra-
thyroidal or extranodal extension, or distant metastasis.
In patients with bilateral thyroid disease and/or bilateral
cervical lymph node involvement, total thyroidectomy
with or without central neck dissection may be indicated.
In instances of lateral neck lymphadenopathy, a respec-
tive lateral neck dissection (levels II-Vb) should also be
performed (Figure 4).
Level of evidence: 2A.
3.4 | Management of follicular and
Hürthle cell carcinomas in low-resource
settings
FTC represents approximately 10% of thyroid carcinoma,
and HTC makes up <2% of thyroid cancers.31 Lymphatic
involvement is rarely observed for FTC whereas HTC has
a propensity for both vascular and lymphatic spread.32
The Bethesda System is commonly used to report thyroid
cytopathology and direct treatment options. Bethesda
Stage III corresponds to a follicular lesion or atypical cells
of undetermined significance, while Bethesda IV indicates
FIGURE 3 Management algorithm for PTC in setting without calcium or thyroid hormone replacement [Color figure can be viewed at
wileyonlinelibrary.com]
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cytopathology identified as a follicular neoplasm or Hürthle
cell lesion/neoplasm.33 However, cytopathology from
FNAC cannot be used reliably to distinguish between
benign and malignant follicular growths, since the diagno-
sis requires histopathologic evidence of vascular or capsular
invasion.34 Thus, Bethesda Stage III and IV classified FNAC
specimens have only an approximate 15% and 25% risk of
ultimately representing a thyroid carcinoma.35
While the Bethesda system is commonly employed
to risk stratify nodules in resource-rich environments,
cytopathology is often not available in low resource
environments. In these situations, if U/S is available, the
TI-RADS classification can be employed to risk stratify
nodules based on ultrasonographic features.36 If neither
cytopathology or U/S are available, then the clinician must
use clinical exam findings such as growth, firmness, pres-
ence of associated lymphadenopathy, and vocal cord paral-
ysis/voice changes in order to risk stratify patients with
thyroid nodules/masses.
Recommendation 12: In a low-resource setting
without thyroid hormone and/or calcium monitoring
and replacement, indeterminate (Bethesda III and IV)
thyroid lesions/neoplasms should generally be observed,
unless the lesion demonstrates highly suspicious ultraso-
nographic features or demonstrates growth over time.
With growth or suspicious ultrasonographic features, thy-
roid lobectomy (or nodulectomy in select cases) may be
considered. The decision for diagnostic thyroid lobectomy
for larger or posteriorly located Bethesda III and IV nod-
ules should be counterbalanced with the understanding
that patients with chronically low thyroid hormone
(without access to thyroid hormone replacement and
monitoring) may have decreased quality of life.
Level of evidence: 2A
Recommendation 13: In a low-resource setting with-
out thyroid hormone and/or calcium monitoring and
replacement, if a diagnostic lobectomy (or nodulectomy in
select cases) indicates minimally invasive follicular carci-
noma or follicular carcinoma with vascular invasion, or if
surgical pathology is unavailable, completion thyroidec-
tomy is not recommended (Figure 5).
Level of evidence: 2A.
Recommendation 14: In a low-resource setting
without thyroid hormone and/or calcium monitoring
and replacement, subtotal thyroidectomy should only be
considered for follicular lesions/neoplasms if there is
bilateral disease, and if the disease can be completely
excised while still preserving sufficient thyroid remnant
and avoiding putting all four parathyroid glands at risk
(Figure 5).
Level of evidence: 2A
Recommendation 15: In the event that postoperative
RAI is not available when considering surgery for a neo-
plasm suspicious for FTC or HTC, total thyroidectomy
should be performed only in cases of bilateral tumor
extension or bilateral cervical lymph node metastases.
Level of evidence: 2A.
3.5 | Management of medullary thyroid
cancer in low-resource settings
Medullary thyroid cancer (MTC) is a rare neuroendocrine
tumor of the parafollicular (C) cells of the thyroid gland,
representing about 2% of thyroid carcinoma cases.37
The majority of MTC occur sporadically, but
FIGURE 4 Management recommendations for PTC in setting without access to RAI therapy [Color figure can be viewed at
wileyonlinelibrary.com]
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approximately 25% of cases are hereditary, associated
with a RET proto-oncogene mutation and multiple endo-
crine neoplasia type 2 (MEN2) syndrome.35 Total thyroid-
ectomy and central compartment dissection are
recommended for MTC management by the NCCN and
ATA guidelines,16,37 but this is predicated on availability
of calcium and thyroid hormone monitoring and replace-
ment after surgery. Elective lateral neck dissection has
been variably advocated based on serum calcitonin
levels,38 although recent investigation suggests that
observation of the lateral neck in the absence of
ultrasonographically apparent neck disease results in
similar biochemical cure and ultimate locoregional
control.39
Recommendation 16: When thyroid and calcium
monitoring and replacement are not available, a total
thyroidectomy cannot be performed for MTC. In these
situations, a lobectomy may be considered for unilateral
MTC thyroid disease, with consideration for an ipsilateral
central neck dissection. For bilateral MTC thyroid dis-
ease, subtotal thyroidectomy may be considered, if the
disease can be completely excised while still preserving
sufficient thyroid remnant and avoiding putting all four
parathyroid glands at risk. Depending upon the burden
of bilateral disease, the risks of hypothyroidism and
hypocalcemia must be balanced with desire for complete
tumor removal.
Level of evidence: 2A.
Recommendation 17: In the absence of radio-
graphically apparent disease in the lateral neck, elective
lateral neck dissection for MTC is generally not rec-
ommended. For patients who do not have access to
ultrasound and/or cross-sectional imaging of the lateral
neck, elective lateral neck may be considered, especially
in cases wherein there is gross disease in the ipsilateral
central neck.
Level of evidence: 2A.
4 | CONCLUSIONS
Successful management of thyroid neoplasms in low-
resource settings often requires adaptation of existing
treatment paradigms. Standard evaluation of thyroid nod-
ules is predicated on the availability of U/S, serum TSH,
thyroid scans, and/or FNAC. Clinical findings and assess-
ment scores such as Wayne's Index provide an alternative
method for evaluating thyroid function in the absence of
serum TSH. Similarly, clinical identification of the fea-
tures of malignant thyroid masses such as rapid growth,
FIGURE 5 Management guidelines for FTC without calcium or thyroid hormone replacement [Color figure can be viewed at
wileyonlinelibrary.com]
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firm mass, thyroid asymmetry, cervical lymphadenopa-
thy, recent onset of hoarseness, and vocal cord paralysis
takes on greater significance in the absence of conven-
tional diagnostic imaging and FNAC.
While definitive surgical resection is the standard
of care for thyroid neoplasms and cancers, extent of
thyroid surgery should be carefully considered in low-
resource settings, especially among populations without
access to calcium and thyroid hormone replacement or
radioactive iodine. For patients with thyroid cancer,
appropriate surgery must be tailored based on a num-
ber of factors including histopathology, disease exten-
sion, and resource availability, as perioperative
complications such as hypocalcemia and/or hypothy-
roidism may be worse than not treating the disease at
all. Referral to higher-resourced environments is occa-
sionally an option and highly encouraged when possi-
ble, but more often than not patients in low-resource
environments simply do not have access to higher
levels of care.
Detailed discussion of cost of specific technologies,
medications, and procedures in various low resource
settings, as well as general solutions for lack of health
care resources globally, are largely beyond the scope of
these guidelines. However, the advent of portable U/S
in particular represents a unique opportunity to intro-
duce relatively low-cost technology for the basic evalu-
ation of thyroid masses.40 Telecytopathology represents
another example of how the integration of technology
and education may contribute to bridging resource
gaps in the evaluation and treatment of thyroid nod-
ules and cancers.41 The integration of new lower cost
technologies into low resource health care environ-
ments should ideally be accompanied by educational
collaborations between developed and developing
countries.42,43
The complete set of AfHNS thyroid nodule and cancer
treatment algorithms can be found at the following link:
https://developingworldheadandneckcancerguidelines.
com/. Overall, these conjoint AfHNS and AHNS Endo-
crine Section guidelines provide a systematic methodology
of evaluating and treating thyroid nodules and cancers
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